The activity of azithromycin (AZI) was evaluated in the beige mouse model of disseminated Mycobacterium avium infection. Mice were infected intravenously with approximately 107 viable M. avium ATCC 49601. AZI at 50, 100, or 200 mg/kg of body weight or clarithromycin (CLA) at 200 mg/kg was given by gavage 5 days per week for 4 weeks. Groups of treated mice were compared with untreated control animals. A dose-related reduction in cell counts in organs was observed with AZI treatment. AZI at 200 mg/kg was more active than CLA at 200 mg/kg against organisms in spleens. The activities of these two agents at 200 mg/kg were comparable against organisms' in lungs. In a second study, AZI at 200 mg/kg was given daily for 5 days; this was followed by intermittent AZI treatment for the next 3 weeks. The activities of AZI given on a three-times-and five-times-per-week basis in the continuation phase were comparable. AZI given on a once-weekly basis was less active. The regimen of AZI given in combination with rifapentine on a once-weekly basis for 8 weeks showed promising activity. Clinical evaluation of AZI and rifapentine will help to define the roles of these agents in the treatment of disseminated M. avium complex infection.
The activity of azithromycin (AZI) was evaluated in the beige mouse model of disseminated Mycobacterium avium infection. Mice were infected intravenously with approximately 107 viable M. avium ATCC 49601. AZI at 50, 100, or 200 mg/kg of body weight or clarithromycin (CLA) at 200 mg/kg was given by gavage 5 days per week for 4 weeks. Groups of treated mice were compared with untreated control animals. A dose-related reduction in cell counts in organs was observed with AZI treatment. AZI at 200 mg/kg was more active than CLA at 200 mg/kg against organisms in spleens. The activities of these two agents at 200 mg/kg were comparable against organisms' in lungs. In a second study, AZI at 200 mg/kg was given daily for 5 days; this was followed by intermittent AZI treatment for the next 3 weeks. The activities of AZI given on a three-times-and five-times-per-week basis in the continuation phase were comparable. AZI given on a once-weekly basis was less active. The regimen of AZI given in combination with rifapentine on a once-weekly basis for 8 weeks showed promising activity. Clinical evaluation of AZI and rifapentine will help to define the roles of these agents in the treatment of disseminated M. avium complex infection.
Azithromycin (AZI) and clarithromycin (CLA) are promising new agents for the treatment of disseminated Mycobacterium avium complex (MAC) infection in individuals with AIDS (7, 19, 23) . We have previously reported on the activities of AZI and CILA in the beige mouse test system (5, 17) and have compared the in vivo activities of these two agents against eight MAC isolates (6). Comparative trials of AZI and CIA in combination with other agents in patients with disseminated MAC infections will be necessary to determine any clinically significant differences in their efficacies and tolerances in this patient population.
One pharmacokinetic advantage of AZI and CLA in the treatment of disseminated MAC infection is the high concentration of drug achieved in tissues (2, 14, 21) . AZI also has a long half-life in serum and tissues, making it potentially useful for intermittent administration (9, 10) .
The purpose of the present study was to compare the activities of AZI and CIA over a longer treatment period than we used in our previous studies and to explore the activity of AZI admi'nistered on an intermittent basis against MAC in the beige mouse test system. The activity of AZI alone and in combination with rifapentine (RPT) against MAC was assessed. (5, 6, 17) . The MICs of AZI and CLA were determined in modified Mueller-Hinton broth (pH 7.4) supplemented with 5% Middlebrook oleic acid-albumin-dextrosecatalase (OADC) enrichment (Difco Laboratories, Detroit, Mich.) (11, 20) . The MIC of RPT was determined in modified 7H10 broth (7H10 agar formulation with agar and malachite green omitted; pH 6.6) supplemented with 5% OADC enrichment (4) . The MICs of AZI, CLA, and RPT (in micrograms per milliliter) for M. avium ATCC 49601 are 8, 4, and 0.125, respectively. A cell suspension with a predominantly (>95%) transparent colonial morphology was used for MIC determinations and infection. The organisms were passaged through beige mice every 3 months to maintain the virulence of the organisms.
MATERIALS
Media. (Fig. 1) .
The increase in cell counts between the early control group and the late control group was significant for organisms in spleens (P < 0.01). Treatment with AZI (at all doses) and CIA reduced organism cell counts in spleens in comparison with the counts in the spleens of mice in both the early and the late control groups (P < 0.01 for all comparisons). The decrease in splenic cell counts between groups receiving AZI at 50 mg/kg and AZI at 100 mg/kg was not significant (P > 0.05); however, the decrease in cell counts in spleens between groups receiving AZI at 50 mg/kg and AZI at 200 mg/kg was significant (P < 0.01). The decrease in cell counts in spleens between groups receiving AZI at 100 mg/kg and AZI at 200 mg/kg was also significant (P < 0.01). Activity of AZI given on an intermittent basis. AZI at 200 mg/kg was given to male mice which had been infected with 1.3 x 10 viable M. avium. AZI was given 5 days per week for the first week and then 1, 3, or 5 days per week for the remaining 3 weeks. A group of AZI-treated mice was sacrificed at the end of the first week of therapy. Mice in control groups were sacrificed at the start of treatment, at the end of the first week of treatment, and at the completion of treatment ( Fig. 2A and  B) .
The increase in cell counts between the early control group, the control group sacrificed after 1 week, and the late control group was significant for organisms in spleens (P < 0.05 for the increase in the number of organisms between the early control group and the control group sacrificed after 1 week; P < 0.01 for the increase in the number of organisms between the control group sacrificed at 1 week and the late control group). One week of AZI therapy reduced organism cell counts in spleens in comparison with the counts in the spleens of mice in each control group (P < 0.01). Treatment with AZI for the remaining 3 weeks at each dosing schedule further reduced organism cell counts in spleens in comparison with the counts in the spleens of the group receiving 1 week of treatment (P < 0.01 for each). There was no significant difference in organism cell counts in spleens between mice given AZI 3 days per week and AZI 5 days per week (P > 0.05). AZI given 1 day per week was less active than AZI given 5 days per week (P < 0.01), but there was no significant difference between AZI given 1 day per week and AZI given 3 days per week (P > 0.05).
The increase in cell counts between the early control group and the control group sacrificed after 1 week of treatment was not significant for organisms in lungs (P > 0.05). The increase in cell counts between the early control group and the late control group was significant (P < 0.01). One with the counts in the lungs of mice in each control group (P < 0.01). AZI given for the remaining 3 weeks at each dosing schedule did not reduce organism cell counts in lungs in comparison with the counts in the lungs of mice in the group receiving 1 week of treatment (P > 0.05).
Intermittent AZI given in combination with RPT. AZI at 200 mg/kg alone and in combination with RPT at 20 mg/kg was given once a week for 8 weeks to female mice which had been infected with 1.1 x 107 viable M. avium. Another group received RPT at 20 mg/kg once weekly (Fig. 3) .
The increase in cell counts between the early control group and the late control group was not significant for organisms in spleens (P > 0.05). Treatment with AZI or RPT as single agents reduced organism cell counts in spleens in comparison with the counts in the spleens of mice in both the early and the late control groups (P < 0.01). AZI plus RPT was more active than either single agent against organisms in spleens (P < 0.01).
The increase in cell counts between the early control group and the late control group was significant for organisms in lungs (P < 0.01). Neither (1, 8, 12, 22) . We have previously reported on the activity of RPT against MAC in the beige mouse test system (15, 16, 18 ). In our current study, AZI and RPT were administered on a once-weekly basis for 8 weeks. AZI plus RPT was more active than either agent used alone. The combination resulted in mean reductions in spleens and lungs of 3.25 and 3.50 log CFU, respectively. It would be of interest to evaluate the efficacy of rifabutin in a similarly designed study, because rifabutin is currently available for clinical use.
Clinical evaluation of AZI in combination with other longacting agents will help to define whether intermittent therapy (once or twice weekly) provides effective treatment for disseminated MAC infection. The potential benefits of intermittent therapy may be decreased adverse drug reactions, decreased drug interactions, and reduced treatment costs.
